THE EFFICACY AND SAFETY OF RITUXIMAB THERAPY IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS
DOI:
https://doi.org/10.54890/.v5i5.484Abstract
Abstract. This article presents the results of a retrospective study of the efficacy and safety of rituximab in 48 children with SLE. Rituximab was administered to patients with a highly active course of the disease with renal and CNS damage, as well as in case of a resistant or relapsing course, the presence of signs of corticosteroid toxicity. The dose of administered drug was 375 mg/m2 weekly, not more than 500 mg per infusion (2-4 infusions) with repeated courses every 6-12 months, depending on the degree of disease activity, the severity of B-cell depletion, the level of hypoimmunoglobulinemia IgG. Rituximab has been shown to treat children with systemic lupus erythematosus more effectively and safely.
Keywords:
children, systemic lupus erythematosus, rituximab, efficacy, safety.References
1. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10-17. https://doi.org/10.1177/0961203314547793
2. Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021;30(11):1829-1836. https://doi.org/10.1177/09612033211034567
3. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatric nephrology. 2017;32(6):1013-1021. https://doi.org/10.1007/s00467-017-3583-x
4. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Pediatric Drugs 2021:23(4):331–347. https://doi.org/10.1007/s40272-021-00457-z
5. Алексеева Е.И., Денисова Р.В., Валиева С.И., Бзарова Т.М., Слепцова Т.В., Чомахидзе А.М. и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504. [Alexeeva E.I., Denisova R.V., Valieva S.I., Bzarova T.M., Sleptsova T.V., Chomakhidze A. M. et al. Efficacy and Safety of Rituximab in Children with Systemic Lupus Erythematosus: Results of a Retrospective Study of the Case Series. Voprosy sovremennoi pediatrii 2016; 15 (5): 497–504 (in Russ.)]. https://doi.org/10.15690/vsp.v15i5.1624
6. Thakral A, Klein-Gitelman MS. An update on treatment and management of pediatric systemic lupus erythematosus. Rheumatology and Therapy. 2016;3(2):209-219. https://doi.org/10.1007/s40744-016-0044-0
7. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78(6):736-745. https://doi.org/10.1136/annrheumdis-2019-215089
8. Арефьева А.Н. Применение ритуксимаба при системной красной волчанке у детей: обзор литературы. Научно-практическая ревматология. 2019;57(5):578-583. [Arefyeva A.N. Use of rituximab in systemic lupus erythematosus in children: a review. Nauchno-Prakticheskaya Revmatologiya. 2019;57(5):578-583 (In Russ.)]. https://doi.org/10.14412/1995-4484-2019-578-583
9. Wise LM, Stohl W. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Frontiers in Medicine. 2020;7:303. https://doi.org/10.3389/fmed.2020.00303
10. Davies R, Sangle S, Jordan N, Aslam L, Lewis M, Wedgwood R et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013,22(6):574–582. https://doi.org/10.1177/0961203313483376
11. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2021;80(1):14-25. https://doi.org/10.1136/annrheumdis-2020-218272
12. Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell therapies in systemic lupus erythematosus. Therapeutics and Clinical Risk Management. 2021;17:39-54. https://doi.org/10.2147/TCRM.S252592
13. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. American Journal of Kidney Diseases. 2020;76(2):265-281. https://doi.org/10.1053/j.ajkd.2019.10.017
14. Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich, CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clinical Immunology. 2019;209: article 108274. https://doi.org/10.1016/j.clim.2019.108274
15. Gunnarsson I, Jonsdottir T. Rituximab treatment in lupus nephritis – where do we stand? Lupus. 2013;22(4):381–389. https://doi.org/10.1177/0961203312471574
16. Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus. 2016;25(10):1086–1096. https://doi.org/10.1177/0961203316652491
17. Федеральный закон от 21.11.2011 N 323-ФЗ (ред. от 26.03.2022) "Об основах охраны здоровья граждан в Российской Федерации" [Federal Law of 21.11. 2011 N 323-FZ (as amended on 26.03.2022) "About the Fundamentals of Protecting the Health of Citizens in the Russian Federation" (in Russ.)]. [Ссылка активна на 10.12.2022]. Режим доступа: https://minzdrav.gov.ru/documents/7025-federalnyy-zakon-323-fz-ot-21-noyabrya-2011-g.
18. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Siciety of Nephrology. 2004;15(2):241-250. https://doi.org/10.1097/01.ASN.0000108969.21691.5D
19. Stolyar L, Lahita RG, Panush RS. Rituximab use as induction therapy for lupus nephritis: a systematic review. Lupus. 2020;29(8):892-912. https://doi.org/10.1177/0961203320928412
20. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. The Journal of Rheumatology. 2015;42(3):541–546. https://doi.org/10.3899/jrheum.140863
21. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. The Journal of Pediatrics. 2006;148(5):623-627. https://doi.org/10.1016/j.jpeds.2006.01.041
22. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology. 2020;59(5):69-81. https://doi.org/10.1093/rheumatology/keaa403
Downloads
Published
How to Cite
Issue
Section
